Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.70 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.70 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NAMPT | P43490 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31745162 | 0.91 | TAS1R3 (0.70) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL31745371 | 0.85 | NAMPT (0.66) | TAS1R3TAS1R1TAS1R2NAMPTMAPT | |
| SCHEMBL702787 | 0.83 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL31745305 | 0.82 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL31745169 | 0.79 | NAMPT (0.59) | TAS1R3TAS1R1TAS1R2NAMPTSMN1; SMN2 | |
| SCHEMBL29663126 | 0.77 | TRPA1 (0.44) | NAMPTSMN1; SMN2KMT2A | |
| SCHEMBL3699382 | 0.77 | TAS1R3 (0.85) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL3697328 | 0.74 | NAMPT (1.00) | TAS1R3TAS1R1TAS1R2NAMPTKMT2A | |
| SCHEMBL21496671 | 0.74 | TRAP1 (0.50) | NAMPTKMT2A | |
| SCHEMBL31745265 | 0.73 | TAS1R3 (0.52) | TAS1R3TAS1R1TAS1R2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667461-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON S AND GAUCHER DISEASE | Children's Hospital Medical Center (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | CHILDRENS HOSPITAL MED CT (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382274-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S AND GAUCHER DISEASE | GBA1, GAA, GBA2 | TAS1R3 4757/4885TAS1R1 4724/4885TAS1R2 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.